Health Canada To Investigate Relenza

Law360, New York (April 10, 2008, 12:00 AM EDT) -- Amid growing worldwide concern over anti-flu drugs, Health Canada has reportedly decided to take a harder look at Relenza in the wake of reports that it can lead to psychotic reactions.

Health Canada opted to take the additional safety step even though the Canadian federal agency updated the labeling for GlaxoSmithKline’s Relenza last month, News Inferno reported on Wednesday.

The U.S. Food and Drug Administration expressed concern in November about the potential side effects of numerous anti-flu drugs.

A majority of the FDA’s Pediatric Advisory Committee...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.